Victor Weigman, Ph.D. | November 21, 2017

Expanding the latest testing in Immuno-Oncology to the clinic

Learn how Immuno-Oncology testing is developed and its implications to the patient
Given light of implications of Microsatellite Instability (MSI) as a pan-cancer therapeutic marker, this presentation outlines the approach to its testing and considerations for providing MSI testing in a clinical setting. 

This presentation highlights how immuno-oncology testing is developed, explanation of output and its implications to the patient. You will explore the current state of mutational burden in trials and considerations for using this across different sized genomic tests, such as RNA sequencing for immune response.

Plus, you will have the opportunity to dive deeper into B/T-Cell repertoire testing, its current impact in clinical trials, use in biomarker discovery and implications to interpretation.

Victor Weigman, Ph.D., Director, Translational Genomics
Jennifer Sims

Related Services:
Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Genomic Assays for Clinical Development

Identifying the right approach from a wealth of potential options

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More